1 of 1 Medicine against Covid19 Evusheld — Photo: Business Wire / Reproduction Anvisa Medicine against Covid19 Evusheld — Photo: Business Wire / Reproduction Anvisa
This was announced by the National Health Surveillance Authority (Anvisa) this Tuesday (7). temporarily suspended Approval for emergency use of the drug Evusheld (Tixagevimab + Cilgavimab) used to treat Covid19.
The drug, manufactured by AstraZeneca, was the first drug with a prophylactic indication to be approved in the country in February 2022. It is a combination of two monoclonal antibodies (cilgavimab + tixagevimab). Its application is by intramuscular injection.
According to Anvisa, the measure comes after data provided by the company showed one significant drop in the drug’s effectiveness against the worrying variants of the new coronavirus circulating in the country.
- INTERFERON: The new drug being tested in Brazil promises to be simpler, cheaper and (perhaps) a ‘silver bullet’ against Covid
- UNDERSTAND: The update of the bivalent Covid vaccine is effective and follows scientific rigor
The suspension of the drug was unanimously approved by Anvisa’s Collegiate Board and is in place pending the submission of data demonstrating the drug’s efficacy versus the variants.
O Evus hero has an indication for use in preexposure prophylaxis and treatment of Covid19 in mild to moderate cases for patients at high risk of disease progression and worsening.
in the same month AstraZeneca reported that it is already testing a new drug in clinical trials that can neutralize new strains of SARSCoV2 and that it is also intended for the prevention of diseases.
O g1 contacted AstraZeneca to ask what stage these studies are at and what the expected completion of the research is.
In the case of Brazil, Anvisa is citing the current prevalence of 77% of BQ.1 variants and 15% of BA.5 variants to temporarily suspend approval.
The agency also points out that if there are batches of the drug on Brazilian territory, the company that holds the approval must duly inform the healthcare professional about the ineffectiveness of the drug against the circulating variants of SarsCov2.